Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

Neurocognitive effects of umami: association with eating behavior and food choice.

Magerowski G, Giacona G, Patriarca L, Papadopoulos K, Garza-Naveda P, Radziejowska J, Alonso-Alonso M.

Neuropsychopharmacology. 2018 Mar 30. doi: 10.1038/s41386-018-0044-6. [Epub ahead of print]

PMID:
29599485
2.

Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.

Goss GD, Vokes EE, Gordon MS, Gandhi L, Papadopoulos KP, Rasco DW, Fischer JS, Chu KL, Ames WW, Mittapalli RK, Lee HJ, Zeng J, Roberts-Rapp LA, Loberg LI, Ansell PJ, Reilly EB, Ocampo CJ, Holen KD, Tolcher AW.

Cancer. 2018 May 15;124(10):2174-2183. doi: 10.1002/cncr.31304. Epub 2018 Mar 13.

PMID:
29533458
3.

A First-in-Human Phase 1 Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.

Tolcher A, Flaherty K, Shapiro GI, Berlin J, Witzig T, Habermann T, Bullock A, Rock E, Elekes A, Lin C, Kostic D, Ohi N, Rasco D, Papadopoulos KP, Patnaik A, Smith L, Cote GM.

Oncologist. 2018 Mar 6. pii: theoncologist.2017-0325. doi: 10.1634/theoncologist.2017-0325. [Epub ahead of print]

PMID:
29511132
4.

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.

Goldman JW, Rosen LS, Tolcher AW, Papadopoulos K, Beeram M, Shi P, Pitou C, Bell R, Kulanthaivel P, Zhang X, Fink A, Chan EM, Shahir A, Farrington D, Patnaik A.

Invest New Drugs. 2017 Dec 1. doi: 10.1007/s10637-017-0532-2. [Epub ahead of print]

PMID:
29196957
5.

trans-Double Bond-Containing Liposomes as Potential Carriers for Drug Delivery.

Giacometti G, Marini M, Papadopoulos K, Ferreri C, Chatgilialoglu C.

Molecules. 2017 Nov 28;22(12). pii: E2082. doi: 10.3390/molecules22122082.

6.

Transcatheter MitraClip implantation facilitated by transthoracic echocardiography.

Chrissoheris MP, Halapas A, Papadopoulos K, Spargias K.

J Echocardiogr. 2017 Nov 27. doi: 10.1007/s12574-017-0358-0. [Epub ahead of print] No abstract available.

PMID:
29181703
7.

Anti-Hu-Associated Autoimmune Limbic Encephalitis in a Patient with PD-1 Inhibitor-Responsive Myxoid Chondrosarcoma.

Papadopoulos KP, Romero RS, Gonzalez G, Dix JE, Lowy I, Fury M.

Oncologist. 2018 Jan;23(1):118-120. doi: 10.1634/theoncologist.2017-0344. Epub 2017 Nov 20.

PMID:
29158368
8.

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.

van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. doi: 10.1007/s00280-017-3451-1. Epub 2017 Oct 26.

10.

Modelling of thrombin generation under flow in realistic left anterior descending geometries.

Papadopoulos KP, Gerotziafas GT, Gavaises M.

Med Eng Phys. 2017 Dec;50:50-58. doi: 10.1016/j.medengphy.2017.10.001. Epub 2017 Oct 16.

PMID:
29050805
11.

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.

Papadopoulos KP, El-Rayes BF, Tolcher AW, Patnaik A, Rasco DW, Harvey RD, LoRusso PM, Sachdev JC, Abbadessa G, Savage RE, Hall T, Schwartz B, Wang Y, Kazakin J, Shaib WL.

Br J Cancer. 2017 Nov 21;117(11):1592-1599. doi: 10.1038/bjc.2017.330. Epub 2017 Oct 3.

12.

Left Ventricular Noncompaction Cardiomyopathy Presenting with Heart Failure in a 35-Year-Old Man.

Papadopoulos K, Petrou PM, Michaelides D.

Tex Heart Inst J. 2017 Aug 1;44(4):260-263. doi: 10.14503/THIJ-15-5371. eCollection 2017 Aug.

13.

Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.

Tachibana M, Papadopoulos KP, Strickler JH, Puzanov I, Gajee R, Wang Y, Zahir H.

Br J Clin Pharmacol. 2018 Jan;84(1):112-121. doi: 10.1111/bcp.13424. Epub 2017 Oct 29.

PMID:
28865153
14.

Explicit analytical tuning rules for digital PID controllers via the magnitude optimum criterion.

Papadopoulos KG, Yadav PK, Margaris NI.

ISA Trans. 2017 Sep;70:357-377. doi: 10.1016/j.isatra.2017.06.020. Epub 2017 Jul 5.

PMID:
28688619
15.

First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors.

Papadopoulos KP, Gluck L, Martin LP, Olszanski AJ, Tolcher AW, Ngarmchamnanrith G, Rasmussen E, Amore BM, Nagorsen D, Hill JS, Stephenson J Jr.

Clin Cancer Res. 2017 Oct 1;23(19):5703-5710. doi: 10.1158/1078-0432.CCR-16-3261. Epub 2017 Jun 27.

PMID:
28655795
16.

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.

Tolcher AW, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, Di Gravio D, Huang B, Gambhire D, Chen Y, Thall AD, Pathan N, Schmidt EV, Chow LQM.

Clin Cancer Res. 2017 Sep 15;23(18):5349-5357. doi: 10.1158/1078-0432.CCR-17-1243. Epub 2017 Jun 20.

PMID:
28634283
17.

The Predictive Value of the Syntax Score in Patients With Chronic Coronary Artery Disease Undergoing Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: A Pilot Study.

Papadopoulos K, Lekakis I, Nicolaides E.

Open Cardiovasc Med J. 2017 Apr 17;11:28-32. doi: 10.2174/1874192401711010028. eCollection 2017.

18.

Trimethylsulfonium Lead Triiodide: An Air-Stable Hybrid Halide Perovskite.

Kaltzoglou A, Stoumpos CC, Kontos AG, Manolis GK, Papadopoulos K, Papadokostaki KG, Psycharis V, Tang CC, Jung YK, Walsh A, Kanatzidis MG, Falaras P.

Inorg Chem. 2017 Jun 5;56(11):6302-6309. doi: 10.1021/acs.inorgchem.7b00395. Epub 2017 May 16.

PMID:
28509542
19.

Orientation and mobility aids for individuals with blindness: Verbal description vs. audio-tactile map.

Papadopoulos K, Koustriava E, Koukourikos P.

Assist Technol. 2017 May 4:1-10. doi: 10.1080/10400435.2017.1307879. [Epub ahead of print]

PMID:
28471302
20.

Purine 5',8-cyclo-2'-deoxynucleoside lesions: formation by radical stress and repair in human breast epithelial cancer cells.

Krokidis MG, Terzidis MA, Efthimiadou E, Zervou SK, Kordas G, Papadopoulos K, Hiskia A, Kletsas D, Chatgilialoglu C.

Free Radic Res. 2017 May;51(5):470-482. doi: 10.1080/10715762.2017.1325485. Epub 2017 May 17.

PMID:
28463089
21.
22.

Symptomatic Type IV Dual Left Anterior Descending Coronary Artery.

Papadopoulos K, Georgiou GM, Nicolaides E.

J Investig Med High Impact Case Rep. 2016 Dec 1;4(4):2324709616683723. doi: 10.1177/2324709616683723. eCollection 2016 Oct-Dec.

23.

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.

Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A.

Br J Cancer. 2017 Feb 28;116(5):575-583. doi: 10.1038/bjc.2017.10. Epub 2017 Feb 2.

24.

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

Infante JR, Patnaik A, Verschraegen CF, Olszanski AJ, Shaheen M, Burris HA, Tolcher AW, Papadopoulos KP, Beeram M, Hynes SM, Leohr J, Lin AB, Li LQ, McGlothlin A, Farrington DL, Westin EH, Cohen RB.

Cancer Chemother Pharmacol. 2017 Feb;79(2):315-326. doi: 10.1007/s00280-016-3205-5. Epub 2017 Jan 17.

PMID:
28097385
25.

Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma.

Ou Y, Doshi S, Nguyen A, Jonsson F, Aggarwal S, Rajangam K, Dimopoulos MA, Stewart AK, Badros A, Papadopoulos KP, Siegel D, Jagannath S, Vij R, Niesvizky R, Graham R, Visich J.

J Clin Pharmacol. 2017 May;57(5):663-677. doi: 10.1002/jcph.850. Epub 2016 Dec 7.

PMID:
27925676
26.

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.

Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Peña C, Xia C, Reif S, Genvresse I, Ramanathan RK.

Ann Oncol. 2016 Oct;27(10):1928-40. doi: 10.1093/annonc/mdw282.

27.

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.

Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR.

J Clin Oncol. 2016 Oct 10;34(29):3562-3569. doi: 10.1200/JCO.2016.68.1106.

28.

Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.

Patnaik A, Tolcher A, Papadopoulos KP, Beeram M, Rasco D, Werner TL, Bauman JW, Scheuber A, Cox DS, Patel BR, Zhou Y, Hamid M, Schramek D, Sharma S.

Cancer Chemother Pharmacol. 2016 Sep;78(3):491-500. doi: 10.1007/s00280-016-3090-y. Epub 2016 Jul 8.

PMID:
27392790
29.

Derivation of flow related risk indices for stenosed left anterior descending coronary arteries with the use of computer simulations.

Papadopoulos KP, Gavaises M, Pantos I, Katritsis DG, Mitroglou N.

Med Eng Phys. 2016 Sep;38(9):929-39. doi: 10.1016/j.medengphy.2016.05.016. Epub 2016 Jul 4.

PMID:
27387905
30.

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.

Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI.

Cancer Discov. 2016 Jul;6(7):740-53. doi: 10.1158/2159-8290.CD-16-0095. Epub 2016 May 23.

31.

Comparison of three orientation and mobility aids for individuals with blindness: Verbal description, audio-tactile map and audio-haptic map.

Papadopoulos K, Koustriava E, Koukourikos P, Kartasidou L, Barouti M, Varveris A, Misiou M, Zacharogeorga T, Anastasiadis T.

Assist Technol. 2017 Spring;29(1):1-7. doi: 10.1080/10400435.2016.1171809. Epub 2016 May 16.

PMID:
27184731
32.

Heavy Lifting Causing Spontaneous Coronary Artery Dissection with Anterior Myocardial Infarction in a 54-Year-Old Woman.

Yiangou K, Papadopoulos K, Azina C.

Tex Heart Inst J. 2016 Apr 1;43(2):189-91. doi: 10.14503/THIJ-15-5097. eCollection 2016 Apr.

33.

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.

Tolcher AW, Bendell JC, Papadopoulos KP, Burris HA, Patnaik A, Fairbrother WJ, Wong H, Budha N, Darbonne WC, Peale F, Mamounas M, Royer-Joo S, Yu R, Portera CC, Infante JR.

Clin Cancer Res. 2016 Sep 15;22(18):4567-73. doi: 10.1158/1078-0432.CCR-16-0308. Epub 2016 Apr 13.

34.

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.

Lee SJ, Levitsky K, Parlati F, Bennett MK, Arastu-Kapur S, Kellerman L, Woo TF, Wong AF, Papadopoulos KP, Niesvizky R, Badros AZ, Vij R, Jagannath S, Siegel D, Wang M, Ahmann GJ, Kirk CJ.

Br J Haematol. 2016 Jun;173(6):884-95. doi: 10.1111/bjh.14014. Epub 2016 Apr 12.

35.

A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.

Infante JR, Mendelson DS, Burris HA 3rd, Bendell JC, Tolcher AW, Gordon MS, Gillenwater HH, Arastu-Kapur S, Wong HL, Papadopoulos KP.

Invest New Drugs. 2016 Apr;34(2):216-24. doi: 10.1007/s10637-016-0327-x. Epub 2016 Feb 29.

PMID:
26924128
36.

A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.

Papadopoulos KP, Lopez-Jimenez J, Smith SE, Steinberg J, Keating A, Sasse C, Jie F, Thyss A.

Leuk Lymphoma. 2016 Aug;57(8):1848-55. doi: 10.3109/10428194.2015.1113275. Epub 2016 Feb 9.

PMID:
26857688
37.

LLLT for the management of patients with ankylosing spondylitis.

Stasinopoulos D, Papadopoulos K, Lamnisos D, Stergioulas A.

Lasers Med Sci. 2016 Apr;31(3):459-69. doi: 10.1007/s10103-016-1874-2. Epub 2016 Jan 21.

PMID:
26796709
38.

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.

Tolcher AW, Papadopoulos KP, Patnaik A, Wilson K, Thayer S, Zanghi J, Gemo AT, Kavanaugh WM, Keer HN, LoRusso PM.

Ann Oncol. 2016 Mar;27(3):526-32. doi: 10.1093/annonc/mdv591. Epub 2015 Dec 8.

PMID:
26646757
39.

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.

Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, Beeram M, Molina JR, Rasco DW, Arcos RR, Kelly CS, Wijayawardana SR, Zhang X, Stancato LF, Bell R, Shi P, Kulanthaivel P, Pitou C, Mulle LB, Farrington DL, Chan EM, Goetz MP.

Clin Cancer Res. 2016 Mar 1;22(5):1095-102. doi: 10.1158/1078-0432.CCR-15-1718. Epub 2015 Nov 18. Erratum in: Clin Cancer Res. 2016 May 15;22(10 ):2596.

40.

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.

Papadopoulos KP, Kelley RK, Tolcher AW, Razak AR, Van Loon K, Patnaik A, Bedard PL, Alfaro AA, Beeram M, Adriaens L, Brownstein CM, Lowy I, Kostic A, Trail PA, Gao B, DiCioccio AT, Siu LL.

Clin Cancer Res. 2016 Mar 15;22(6):1348-55. doi: 10.1158/1078-0432.CCR-15-1221. Epub 2015 Oct 21.

41.

A cardiac haemangioma: the contribution of myocardial contrast echocardiography in the diagnosis.

Papadopoulos K, Makrides CA, Eleutheriou E.

BMJ Case Rep. 2015 Jul 6;2015. pii: bcr2015210075. doi: 10.1136/bcr-2015-210075.

42.

A Family of Potent Ru(II) Photosensitizers with Enhanced DNA Intercalation: Bimodal Photokillers.

Pefkianakis EK, Theodossiou TA, Toubanaki DK, Karagouni E, Falaras P, Papadopoulos K, Vougioukalakis GC.

Photochem Photobiol. 2015 Sep-Oct;91(5):1191-202. doi: 10.1111/php.12485. Epub 2015 Aug 8.

PMID:
26118404
43.

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW.

Clin Cancer Res. 2015 Oct 1;21(19):4286-93. doi: 10.1158/1078-0432.CCR-14-2607. Epub 2015 May 14.

44.

Perioperative use of iloprost in cardiac surgery patients diagnosed with heparin-induced thrombocytopenia-reactive antibodies or with true HIT (HIT-reactive antibodies plus thrombocytopenia): An 11-year experience.

Palatianos G, Michalis A, Alivizatos P, Lacoumenda S, Geroulanos S, Karabinis A, Iliopoulou E, Soufla G, Kanthou C, Khoury M, Sfyrakis P, Stavridis G, Astras G, Vassili M, Antzaka C, Marathias K, Kriaras I, Tasouli A, Papadopoulos K, Katafygioti M, Matoula N, Angelidis A, Melissari E.

Am J Hematol. 2015 Jul;90(7):608-17. doi: 10.1002/ajh.24017.

45.

Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor.

Papadopoulos KP, Isaacs R, Bilic S, Kentsch K, Huet HA, Hofmann M, Rasco D, Kundamal N, Tang Z, Cooksey J, Mahipal A.

Cancer Chemother Pharmacol. 2015 May;75(5):887-95. doi: 10.1007/s00280-015-2712-0. Epub 2015 Feb 27.

PMID:
25721064
46.

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS.

Clin Cancer Res. 2015 Feb 15;21(4):739-48. doi: 10.1158/1078-0432.CCR-14-1901. Epub 2014 Dec 16.

47.

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.

Tolcher AW, Patnaik A, Papadopoulos KP, Rasco DW, Becerra CR, Allred AJ, Orford K, Aktan G, Ferron-Brady G, Ibrahim N, Gauvin J, Motwani M, Cornfeld M.

Cancer Chemother Pharmacol. 2015 Jan;75(1):183-9. doi: 10.1007/s00280-014-2615-5. Epub 2014 Nov 25.

PMID:
25417902
48.

Generic Penetration Within Top-10 Genericized Molecules - Greece Versus Major European Countries.

Charitonidis S, Kofinas K, Katsoulakis M, Papadopoulos K, Ollandezos M, Kyriopoulos J.

Value Health. 2014 Nov;17(7):A411-2. doi: 10.1016/j.jval.2014.08.976. Epub 2014 Oct 26. No abstract available.

49.

Quantification of Switching Trends in the Greek Pharmaceutical Market During the Period Of Crisis.

Ollandezos M, Charitonidis S, Papadopoulos K, Katsoulakis M, Kofinas K, Kyriopoulos J.

Value Health. 2014 Nov;17(7):A409. doi: 10.1016/j.jval.2014.08.961. Epub 2014 Oct 26. No abstract available.

50.

Letting The Data Speak: A Shift of the Pharmaceutical Spending to Households in Greece.

Kyriopoulos D, Ollandezos M, Papadopoulos K, Kyriopoulos II, Pentafragas V.

Value Health. 2014 Nov;17(7):A407. doi: 10.1016/j.jval.2014.08.952. Epub 2014 Oct 26. No abstract available.

Supplemental Content

Loading ...
Support Center